Quarterly report pursuant to Section 13 or 15(d)

7. INTANGIBLE ASSETS

v3.10.0.1
7. INTANGIBLE ASSETS
 9 Months Ended
Sep. 30, 2018
Intangible Assets  
7. INTANGIBLE ASSETS

Intangible assets at September 30, 2018 and December 31, 2017 consist of the following:

 

 

    September 30, 2018   December 31, 2017
        Accumulated            Accumulated     
    Cost   Amortization   Net   Cost   Amortization   Net
Trademark and other intangible rights related to Nabi-HB    $      4,100,046    $          780,961    $   3,319,085    $    4,100,046    $          341,670    $   3,758,376
Rights to intermediates               907,421                172,842            734,579             907,421                  75,618            831,803
Customer contract            1,076,557                914,575            161,982          1,076,557                817,386            259,171
     $      6,084,024    $       1,868,378    $   4,215,646    $    6,084,024    $       1,234,674    $   4,849,350

 

All of the Company’s intangible assets were acquired in the Biotest Transaction. Amortization expense related to these intangible assets for the three and nine months ended September 30, 2018 was $0.2 million and $0.6 million, respectively. Amortization expense for the three and nine months ended September 30, 2017 was $0.3 million. Estimated aggregate future aggregate amortization expense for the next five years is expected to be as follows:

 

Remainder of 2018      $            211,435
2019                    844,938
2020                    715,352
2021                    715,352
2022                    715,352